Literature DB >> 23538569

Challenging behavior in Smith-Lemli-Opitz syndrome: initial test of biobehavioral influences.

Kurt A Freeman1, Rose Eagle, Louise S Merkens, Darryn Sikora, Kersti Pettit-Kekel, Mina Nguyen-Driver, Robert D Steiner.   

Abstract

OBJECTIVE: To study challenging behavior (destruction, aggression, self-injury, stereotypy) in children with Smith-Lemli-Opitz syndrome (SLOS) using a biobehavioral model that helps distinguish biological from socially mediated variables influencing the behavior.
BACKGROUND: SLOS is an autosomal-recessive syndrome of multiple malformations and intellectual disability resulting from a genetic error in cholesterol synthesis in all cells and tissues, including brain. The exact cause of the challenging behavior in SLOS is unclear, but defective brain cholesterol synthesis may contribute. Because the precise genetic and biochemical etiology of SLOS is known, this disorder is a good model for studying biological causes of challenging behavior.
METHOD: In a preliminary application of a biobehavioral model, we studied the association between cholesterol levels (as a biochemical indicator of disease severity) and behavior subtype ("biological" vs "learned") in 13 children with SLOS. Parents completed a questionnaire that categorized challenging behavior as influenced primarily by social or nonsocial (thus, presumably biological) factors.
RESULTS: The severity of the cholesterol synthesis defect correlated significantly with behavior subtype classification for 1 of 2 challenging behaviors. Greater severity of the cholesterol synthesis defect was associated with behavior being classified as primarily influenced by biological factors.
CONCLUSION: The interplay between challenging behavior and defective cholesterol synthesis in SLOS may help explain biological influences on the behavior. Our findings have implications for research on the effectiveness of behavioral and medical treatments for behavioral difficulties in SLOS and other neurodevelopmental disorders.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23538569      PMCID: PMC3684260          DOI: 10.1097/WNN.0b013e31828bf6d5

Source DB:  PubMed          Journal:  Cogn Behav Neurol        ISSN: 1543-3633            Impact factor:   1.600


  49 in total

Review 1.  RSH (so-called Smith-Lemli-Opitz) syndrome.

Authors:  J M Opitz
Journal:  Curr Opin Pediatr       Date:  1999-08       Impact factor: 2.856

2.  The Motivation Assessment Scale: reliability and construct validity across three topographies of behavior.

Authors:  P C Duker; J Sigafoos
Journal:  Res Dev Disabil       Date:  1998 Mar-Apr

3.  Clinical effects of cholesterol supplementation in six patients with the Smith-Lemli-Opitz syndrome (SLOS)

Authors:  E R Elias; M B Irons; A D Hurley; G S Tint; G Salen
Journal:  Am J Med Genet       Date:  1997-01-31

4.  A new face for an old syndrome.

Authors:  R I Kelley
Journal:  Am J Med Genet       Date:  1997-01-31

Review 5.  Smith-Lemli-Opitz syndrome: a treatable inherited error of metabolism causing mental retardation.

Authors:  M J Nowaczyk; D T Whelan; T W Heshka; R E Hill
Journal:  CMAJ       Date:  1999-07-27       Impact factor: 8.262

6.  Cholesterol and bile acid replacement therapy in children and adults with Smith-Lemli-Opitz (SLO/RSH) syndrome.

Authors:  N A Nwokoro; J J Mulvihill
Journal:  Am J Med Genet       Date:  1997-01-31

7.  Smith-Lemli-Opitz syndrome is caused by mutations in the 7-dehydrocholesterol reductase gene.

Authors:  H R Waterham; F A Wijburg; R C Hennekam; P Vreken; B T Poll-The; L Dorland; M Duran; P E Jira; J A Smeitink; R A Wevers; R J Wanders
Journal:  Am J Hum Genet       Date:  1998-08       Impact factor: 11.025

8.  Mutations in the Delta7-sterol reductase gene in patients with the Smith-Lemli-Opitz syndrome.

Authors:  B U Fitzky; M Witsch-Baumgartner; M Erdel; J N Lee; Y K Paik; H Glossmann; G Utermann; F F Moebius
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-07       Impact factor: 11.205

9.  Mutations in the human sterol delta7-reductase gene at 11q12-13 cause Smith-Lemli-Opitz syndrome.

Authors:  C A Wassif; C Maslen; S Kachilele-Linjewile; D Lin; L M Linck; W E Connor; R D Steiner; F D Porter
Journal:  Am J Hum Genet       Date:  1998-07       Impact factor: 11.025

10.  Smith-Lemli-Opitz syndrome: a variable clinical and biochemical phenotype.

Authors:  A K Ryan; K Bartlett; P Clayton; S Eaton; L Mills; D Donnai; R M Winter; J Burn
Journal:  J Med Genet       Date:  1998-07       Impact factor: 6.318

View more
  6 in total

1.  A Pilot Study of the Association of Markers of Cholesterol Synthesis with Disturbed Sleep in Smith-Lemli-Opitz Syndrome.

Authors:  Kurt A Freeman; Erin Olufs; Megan Tudor; Jean-Baptiste Roullet; Robert D Steiner
Journal:  J Dev Behav Pediatr       Date:  2016-06       Impact factor: 2.225

2.  Disorders of cholesterol metabolism and their unanticipated convergent mechanisms of disease.

Authors:  Frances M Platt; Christopher Wassif; Alexandria Colaco; Andrea Dardis; Emyr Lloyd-Evans; Bruno Bembi; Forbes D Porter
Journal:  Annu Rev Genomics Hum Genet       Date:  2014       Impact factor: 8.929

3.  Feeding impairments associated with plasma sterols in Smith-Lemli-Opitz syndrome.

Authors:  Mark J Merkens; Nancy L Sinden; Christine D Brown; Louise S Merkens; Jean-Baptiste Roullet; Thuan Nguyen; Robert D Steiner
Journal:  J Pediatr       Date:  2014-07-16       Impact factor: 4.406

4.  Pathogenesis, Epidemiology, Diagnosis and Clinical Aspects of Smith-Lemli-Opitz Syndrome.

Authors:  Simona E Bianconi; Joanna L Cross; Christopher A Wassif; Forbes D Porter
Journal:  Expert Opin Orphan Drugs       Date:  2015-03       Impact factor: 0.694

5.  Development, behavior, and biomarker characterization of Smith-Lemli-Opitz syndrome: an update.

Authors:  Audrey Thurm; Elaine Tierney; Cristan Farmer; Phebe Albert; Lisa Joseph; Susan Swedo; Simona Bianconi; Irena Bukelis; Courtney Wheeler; Geeta Sarphare; Diane Lanham; Christopher A Wassif; Forbes D Porter
Journal:  J Neurodev Disord       Date:  2016-04-05       Impact factor: 4.025

6.  Biochemical and Clinical Effects of Vitamin E Supplementation in Hungarian Smith-Lemli-Opitz Syndrome Patients.

Authors:  Katalin Koczok; László Horváth; Zeljka Korade; Zoltán András Mezei; Gabriella P Szabó; Ned A Porter; Eszter Kovács; Károly Mirnics; István Balogh
Journal:  Biomolecules       Date:  2021-08-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.